PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased ... market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges ... guidance for a second time this year. Now, the company is forecasting a low-single ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full ... determine future revaccination schedules AREXVY is the world’s first RSV vaccine ...

Per the company, Arexvy is the only RSV vaccine with efficacy and safety data available through three full RSV seasons. The vaccine’s safety and reactogenicity data were similar to that observed ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...

Arexvy shows 62.9% efficacy against RSV-LRTD ... This vaccine is the only one with efficacy and safety data available through 3 full seasons, including in individuals at increased risk due to ...

The U.S. Centers for Disease Control and Prevention decided to hold off recommending the use of the vaccine, Arexvy, in ...

But more importantly, I think GKS has two major growth drivers, Shingrix and Arexvy. This is why I believe its current relative undervaluation seems unjustified. Thus, I believe GSK is now a ...

Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%. Vaccine sales are expected to decrease at low-single-digit percent.

Arexvy performance was impacted by three factors ... so it's important Jemperli is now available to these patients. Zejula's growth continued in Q3 driven by U.S. pricing effects and high demand ...